Skip to main content
Top
Published in: Pathology & Oncology Research 2/2017

01-04-2017 | Short Communication

The Missing Link in the Diagnostic Pathway of Prostate Cancer

Authors: Arne Vidar Tind Wøyen, Gergely Laczkó, Søren Høyer, Laszlo Hegyi

Published in: Pathology & Oncology Research | Issue 2/2017

Login to get access

Abstract

Prostate cancer is one of the most common cancers in the Western world. It is among the leading causes of cancer related death. While its incidence and survival increased significantly during the last few decades in Denmark, the mortality rate did not change for patients younger than 80 year old. Development of new techniques, such as multiparametric MRI, helps to increase the accuracy of diagnosis. However, a missing link in the diagnostic pathway may result in mistreatment if an acinar adenocarcinoma of prostate is transformed into a neuroendocrine phenotype such as small cell carcinoma.
Literature
3.
go back to reference Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 34:22–29CrossRefPubMed Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 34:22–29CrossRefPubMed
4.
go back to reference Spiess PE, Pettaway CA, Vakar-Lopez F et al (2007) Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110:1729–1737CrossRefPubMed Spiess PE, Pettaway CA, Vakar-Lopez F et al (2007) Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110:1729–1737CrossRefPubMed
5.
go back to reference Li Z, Sun Y, Chen X et al (2015) P 53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res 13:584–591CrossRefPubMed Li Z, Sun Y, Chen X et al (2015) P 53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res 13:584–591CrossRefPubMed
7.
go back to reference Burchardt T, Burchardt M, Chen MW et al (1999) Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162:1800–1805CrossRefPubMed Burchardt T, Burchardt M, Chen MW et al (1999) Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162:1800–1805CrossRefPubMed
8.
go back to reference Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637PubMed Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637PubMed
Metadata
Title
The Missing Link in the Diagnostic Pathway of Prostate Cancer
Authors
Arne Vidar Tind Wøyen
Gergely Laczkó
Søren Høyer
Laszlo Hegyi
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0183-1

Other articles of this Issue 2/2017

Pathology & Oncology Research 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine